Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 87484 refers to a laboratory test specifically designed for the detection of the infectious agent Ehrlichia chaffeensis through the use of nucleic acid amplification techniques, which can involve either DNA or RNA. Ehrlichia chaffeensis is classified as a gram-negative rickettsial bacterium that is primarily transmitted to humans via tick bites. Infection with this bacterium can lead to human monocytic ehrlichiosis, a condition characterized by flu-like symptoms that may escalate to severe complications, including multisystem toxic-shock type disease, meningitis, or adult respiratory distress syndrome if left untreated. The detection of Ehrlichia chaffeensis is accomplished through advanced molecular techniques such as polymerase chain reaction (PCR), which allows for the amplification of specific DNA or RNA sequences associated with the pathogen. This process is crucial for identifying the presence of the bacterium in a patient's sample, as it can significantly impact clinical management and treatment decisions. The test utilizes methods like real-time polymerase chain reaction (qPCR) or reverse transcription polymerase chain reaction (RT-PCR) for RNA detection, ensuring high sensitivity and specificity in identifying the pathogen. By exponentially amplifying the target nucleic acid sequences, the test can provide rapid and accurate results, which are essential for timely intervention in affected patients.
© Copyright 2026 Coding Ahead. All rights reserved.
The CPT® Code 87484 is indicated for the detection of Ehrlichia chaffeensis in patients who present with symptoms consistent with human monocytic ehrlichiosis. The following conditions may warrant the use of this test:
The procedure for detecting Ehrlichia chaffeensis using CPT® Code 87484 involves several critical steps that ensure accurate identification of the pathogen's nucleic acid. The process begins with the collection of a biological sample, typically blood, from the patient. This sample is then subjected to nucleic acid extraction, where the DNA or RNA is isolated from the cells present in the sample. Following extraction, the nucleic acid is amplified using polymerase chain reaction (PCR) techniques. In the case of RNA, reverse transcription is performed first, converting the RNA into complementary DNA (cDNA) using reverse transcriptase. The cDNA is then placed in a PCR tube along with specific DNA primers, a polymerase enzyme, and fluorescent dyes or probes. The PCR process begins with denaturation, where the DNA is heated to separate it into single strands. As the temperature decreases, the primers bind to their complementary sequences on the single-stranded DNA, and the polymerase enzyme synthesizes new strands, resulting in the formation of double-stranded DNA. This amplification cycle is repeated approximately 35-40 times, exponentially increasing the quantity of the target DNA. In real-time PCR, the amplification is monitored through the use of fluorescent or chemiluminescent probes that specifically bind to the target sequence, allowing for the quantification of the nucleic acid present in the sample. The fluorescence emitted during each cycle is measured, providing real-time data on the amount of Ehrlichia chaffeensis nucleic acid detected.
After the completion of the nucleic acid detection procedure using CPT® Code 87484, the laboratory generates a report detailing the results of the test. This report includes information on the presence or absence of Ehrlichia chaffeensis nucleic acid, as well as quantitative data indicating the relative amounts of the detected nucleic acid. Clinicians can use this information to guide treatment decisions and further management of the patient. It is essential for healthcare providers to interpret the results in conjunction with clinical findings and patient history. Follow-up care may be necessary, especially for patients who test positive, to monitor for potential complications associated with the infection. Additionally, proper documentation of the test results and any subsequent clinical actions taken is crucial for maintaining compliance and ensuring continuity of care.
| Short Descr | EHRLICHA CHAFFEENSIS AMP PRB | Medium Descr | IADNA EHRLICHIA CHAFFEENSIS AMPLIFIED PROBE TQ | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe technique | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Added | Code added. |
Get instant expert-level medical coding assistance.